Octreotide Off-Label Indications and Usage

Gastrointestinal Disorders

Octreotide is beneficial for refractory dumping syndrome after gastric, esophageal, or bariatric surgery, with the American College of Endocrinology recommending a starting dose of 50 mcg subcutaneously before meals 1, 2, 3
Multiple controlled trials demonstrate octreotide reduces both early dumping symptoms (vasomotor symptoms, tachycardia) and late dumping symptoms (hypoglycemia) in patients with dumping syndrome 1, 2
Long-term treatment (mean 15-93 months) provides sustained symptom control with minimal side effects in patients with dumping syndrome 2

Octreotide may be beneficial for syncope due to refractory recurrent postprandial or neurogenic orthostatic hypotension, with the ACC/AHA/HRS guidelines (2017) recommending octreotide when other treatments fail 4
Mechanism: reduces splanchnic blood flow by approximately 20%, preventing postprandial hypotension and improving orthostatic tolerance in patients with orthostatic hypotension 4

For loperamide-refractory chemotherapy-induced diarrhea, octreotide 500 mcg three times daily subcutaneously is recommended, with the German Society of Hematology and Oncology guidelines recommending octreotide as second-line therapy after loperamide failure 5
Octreotide can be considered for radiation therapy-induced diarrhea refractory to loperamide, with the same dosing as chemotherapy-induced diarrhea: 500 mcg three times daily subcutaneously 5, 6
For malignant bowel obstruction when gut function is no longer possible, octreotide is recommended early in diagnosis because of its efficacy and tolerability, with the NCCN Palliative Care guidelines supporting octreotide use in this setting 7

The European Society for Clinical Nutrition and Metabolism recommends 50 mcg subcutaneously twice daily for antisecretory effects in patients with short bowel syndrome 3

Monitor for hypoglycemia, especially in diabetic patients, as octreotide inhibits insulin secretion 1, 2
Do not use octreotide for incomplete bowel obstruction with metoclopramide simultaneously, as metoclopramide increases GI motility and should not be used in complete obstruction 7
Exclude infectious causes of diarrhea before starting octreotide 5, 6